Triple Agonist 30mg — Verification Report
From Phase One Labz · Lot P1-30RT06 · Tested July 2026
VialTalk
Triple Agonist 30mg
Phase One Labz
Score
103
Grade
A++
Superlative
Cap color: Unresolved(not recorded; the report and the submitter did not confirm it)
Lot P1-30RT06
Tested July 2026
Report ID
552f8048
Test
Method
Result
Status
PurityFull credit
HPLC
99.92%
Full credit
IdentityStrong
HPLC retention time
Consistent
Strong
ContentStrong
Gravimetric vs label claim
30 mg labeled · 30.88 mg tested
Strong
EndotoxinFull credit
USP <85> compendial
Screened
Full credit
Heavy metalsFull credit
ICP-MS
Screened
Full credit
SterilityPartial
PCR / DNA microarray
Screened
Partial
Batch conformityPartial
Two-batch average
Assessed
Partial
Additional screens, not scoredFentanyl screen
Verified against the submitted certificate. VialTalk received this vendor's certificate, checked each test against the reported method, and scored it under a published methodology. Tests the vendor did not submit are listed above rather than omitted. Scores above 100 reflect laboratory credibility weighting.
This report is issued by VialTalk. It is not a laboratory certificate.Scoring methodology →
Canonical source: https://vialtalk.com/vendors/phase-one-labz/coas/552f8048-59c5-49c1-825d-9f4667175178